New device QMSR includes significant changes for combination products - Hogan Lovells Cadwalader
New device QMSR introduces significant changes for combination products, impacting compliance requirements for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All manufacturers of combination products, including branded drug makers and generic/ANDA manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Introduction of new quality management system regulations for combination products, requiring adjustments in compliance processes.
Who it affects
All manufacturers of combination products, including branded drug makers and generic/ANDA manufacturers.
What you must do
Review and update quality management systems to align with the new QMSR requirements.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Biden administration and drug manufacturer ask court to block suspension of mifepristone approval - SCOTUSblog
- FCC Holds Calls About Free Clinical Pharmaceutical Trials Are Not “Advertising” Under the TCPA - Consumer Financial Services Law Monitor
- Strides Pharma Science Completes US-FDA Inspection, Receives Form 483 with Four Procedural Observations - scanx.trade
- Nebraska Addiction Treatment Rules Proposal - Legal Reader
- How a new FDA rule may change pharmaceutical advertising. - psychologytoday.com